Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer
Open Access
- 1 November 1995
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 72 (5) , 1267-1269
- https://doi.org/10.1038/bjc.1995.498
Abstract
Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.Keywords
This publication has 4 references indexed in Scilit:
- Phase I and pharmacokinetic study of rhizoxin.1992
- Rhizoxin binding to tubulin at the maytansine-binding siteBiochimica et Biophysica Acta (BBA) - General Subjects, 1987
- RHIZOXIN, A MACROCYCLIC LACTONE ANTIBIOTIC, AS A NEW ANTITUMOR AGENT AGAINST HUMAN AND MURINE TUMOR-CELLS AND THEIR VINCRISTINE-RESISTANT SUBLINES1986
- Reporting results of cancer treatmentCancer, 1981